TO WHAT EXTENT ARE THE LEARNINGS FROM THE INTRODUCTION OF BIOSIMILARS IN INFLAMMATORY DISEASES TRANSFERABLE TO THE FUTURE INTRODUCTION OF BIOSIMILARS IN ONCOLOGY?

被引：0
|
作者：
Klebba, S. [1 ]
Makin, D. [1 ]
Teale, C. W. [2 ]
机构：
[1] GfK, London, England
[2] GfK, Melton Mowbray, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2321
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN245
引用
收藏
页码：A753 / A753
页数：1
相关论文
共 37 条
  • [21] Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?
    Schreiber, S.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (08): : 689 - 694
  • [22] Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
    Strand, Vibeke
    Goncalves, Joao
    Hickling, Timothy P.
    Jones, Heather E.
    Marshall, Lisa
    Isaacs, John D.
    BIODRUGS, 2020, 34 (01) : 27 - 37
  • [23] Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
    Vibeke Strand
    Joao Gonçalves
    Timothy P. Hickling
    Heather E. Jones
    Lisa Marshall
    John D. Isaacs
    BioDrugs, 2020, 34 : 27 - 37
  • [24] Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
    Vibeke Strand
    Joao Gonçalves
    Timothy P. Hickling
    Heather E. Jones
    Lisa Marshall
    John D. Isaacs
    BioDrugs, 2020, 34 : 253 - 253
  • [25] INTRODUCTION. WHAT IS ENVIRONMENTAL ETHICS? FROM ITS ROOTS TO THE FUTURE
    Valera, Luca
    CUADERNOS DE BIOETICA, 2016, 27 (91): : 289 - 292
  • [26] Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019
    Wang, Ching-Yu
    Heldermon, Coy D.
    Vouri, Scott M.
    Park, Haesuk
    Wheeler, Sarah E.
    Ramnaraign, Brian Hemendra
    Dang, Nam Hoang
    Brown, Joshua D.
    JAMA NETWORK OPEN, 2021, 4 (11) : E2133474
  • [27] Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
    Dipasquale, V.
    Pellegrino, S.
    Cucinotta, U.
    Citrano, M.
    Graziano, F.
    Cappello, M.
    Busacca, A.
    Orlando, A.
    Accomando, S.
    Romano, C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I419 - I419
  • [28] Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody
    Isaacs, J. D.
    Cutolo, M.
    Keystone, E. C.
    Park, W.
    Braun, J.
    JOURNAL OF INTERNAL MEDICINE, 2016, 279 (01) : 41 - 59
  • [29] Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
    Dipasquale, V.
    Pellegrino, S.
    Cucinotta, U.
    Citrano, M.
    Graziano, F.
    Cappello, M.
    Busacca, A.
    Orlando, A.
    Accomando, S.
    Romano, C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I419 - I419
  • [30] EFFICACY AND SAFETY OF BIOSIMILARS OF ANTI-TNF-APLHA IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
    Dipasquale, V
    Pellegrino, S.
    Ventimiglia, M.
    Cucinotta, U.
    Citrano, M.
    Graziano, F.
    Cappello, M.
    Busacca, A.
    Orlando, A.
    Accomando, S.
    Romano, C.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S141 - S142
1234